Ratings by Janney (Paul Knight)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
4/15/2020 Interpace Diagnostics Group Inc IDXG New Coverage Buy
(N/A)
4.81
(3.92)
-18.5% Details
2/11/2020 Fluidigm Corporation FLDM Maintain Neutral
(N/A)
 
 
  Details
11/26/2019 T2 Biosystems, Inc TTOO Downgrade Neutral
(Buy)
1.42
(1.03)
-27.46% Details
11/6/2019 Fluidigm Corporation FLDM Downgrade Neutral
(Buy)
5.11
(7.41)
45.01% Details
9/12/2019 T2 Biosystems, Inc TTOO Upgrade Buy
(Neutral)
2.61
(1.42)
-45.59% Details
7/24/2019 Champions Oncology CSBR Downgrade Neutral
(Buy)
7.21
(10.45)
44.94% Details
7/2/2019 Bio-Techne Corp. TECH Upgrade Buy
(Neutral)
208.49
(482.24)
131.3% Details
6/28/2019 Avid Bioservices CDMO Upgrade Buy
(Neutral)
4.00
(25.65)
541.25% Details
6/14/2019 Avantor Inc. AVTR New Coverage Buy
(N/A)
18.19
(37.58)
106.6% Details
2/25/2019 Danaher DHR Upgrade Buy
(Neutral)
113.48
(297.49)
162.15% Details
1/29/2019 OncoCyte Corp OCX Upgrade Buy
(Neutral)
1.82
(5.14)
182.42% Details
1/3/2019 Fluidigm Corporation FLDM Upgrade Buy
(Neutral)
8.62
(5.11)
-40.72% Details
11/29/2018 Veracyte, Inc VCYT Maintain Buy
(N/A)
 
 
  Details
11/2/2018 PerkinElmer PKI Downgrade Neutral
(Buy)
86.48
(182.23)
110.72% Details
10/31/2018 Veracyte, Inc VCYT Upgrade Buy
(Neutral)
9.44
(12.13)
28.5% Details
10/30/2018 Neogenomics NEO Maintain Buy
(N/A)
 
 
  Details
10/3/2018 Repligen RGEN Maintain Buy
(N/A)
 
 
  Details
10/2/2018 West Pharmaceutical WST Maintain Buy
(N/A)
 
 
  Details
9/10/2018 OncoCyte Corp OCX Maintain Buy
(N/A)
 
 
  Details